TY - JOUR
T1 - Phenotypic characteristics and asthma severity in an East African cohort of adults and adolescents with asthma
T2 - findings from the African severe asthma project
AU - Kirenga, Bruce
AU - Chakaya, Jeremiah
AU - Yimer, Getnet
AU - Nyale, George
AU - Haile, Tewodros
AU - Muttamba, Winters
AU - Mugenyi, Levicatus
AU - Katagira, Winceslaus
AU - Worodria, William
AU - Aanyu-Tukamuhebwa, Hellen
AU - Lugogo, Njira
AU - Joloba, Moses
AU - Bekele, Amsalu
AU - Makumbi, Fred
AU - Green, Cindy
AU - de Jong, Corina
AU - Kamya, Moses
AU - van der Molen, Thys
N1 - Funding: The study was funded by a project grant from the GSK Africa Non-Communicable Disease Open Lab (Project number: 8019).
PY - 2020/2/12
Y1 - 2020/2/12
N2 - Rationale: The relationship between clinical and biomarker characteristics of asthma and its severity in Africa is not well known.Methods: Using the Expert Panel Report 3, we assessed for asthma severity and its relationship with key phenotypic characteristics in Uganda, Kenya and Ethiopia. The characteristics included adult onset asthma, family history of asthma, exposures (smoking and biomass), comorbidities (HIV, hypertension, obesity, tuberculosis (TB), rhinosinusitis, gastro-oesophageal disease (GERD) and biomarkers (fractional exhaled nitric oxide (FeNO), skin prick test (SPT) and blood eosinophils). We compared these characteristics on the basis of severity and fitted a multivariable logistic regression model to assess the independent association of these characteristics with asthma severity.Results: A total of 1671 patients were enrolled, 70.7% women, with median age of 40 years. The prevalence of intermittent, mild persistent, moderate persistent and severe persistent asthma was 2.9%, 19.9%, 42.6% and 34.6%, respectively. Only 14% were on inhaled corticosteroids (ICS). Patients with severe persistent asthma had a higher rate of adult onset asthma, smoking, HIV, history of TB, FeNO and absolute eosinophil count but lower rates of GERD, rhinosinusitis and SPT positivity. In the multivariate model, Ethiopian site and a history of GERD remained associated with asthma severity.Discussion: The majority of patients in this cohort presented with moderate to severe persistent asthma and the use of ICS was very low. Improving access to ICS and other inhaled therapies could greatly reduce asthma morbidity in Africa.
AB - Rationale: The relationship between clinical and biomarker characteristics of asthma and its severity in Africa is not well known.Methods: Using the Expert Panel Report 3, we assessed for asthma severity and its relationship with key phenotypic characteristics in Uganda, Kenya and Ethiopia. The characteristics included adult onset asthma, family history of asthma, exposures (smoking and biomass), comorbidities (HIV, hypertension, obesity, tuberculosis (TB), rhinosinusitis, gastro-oesophageal disease (GERD) and biomarkers (fractional exhaled nitric oxide (FeNO), skin prick test (SPT) and blood eosinophils). We compared these characteristics on the basis of severity and fitted a multivariable logistic regression model to assess the independent association of these characteristics with asthma severity.Results: A total of 1671 patients were enrolled, 70.7% women, with median age of 40 years. The prevalence of intermittent, mild persistent, moderate persistent and severe persistent asthma was 2.9%, 19.9%, 42.6% and 34.6%, respectively. Only 14% were on inhaled corticosteroids (ICS). Patients with severe persistent asthma had a higher rate of adult onset asthma, smoking, HIV, history of TB, FeNO and absolute eosinophil count but lower rates of GERD, rhinosinusitis and SPT positivity. In the multivariate model, Ethiopian site and a history of GERD remained associated with asthma severity.Discussion: The majority of patients in this cohort presented with moderate to severe persistent asthma and the use of ICS was very low. Improving access to ICS and other inhaled therapies could greatly reduce asthma morbidity in Africa.
U2 - 10.1136/bmjresp-2019-000484
DO - 10.1136/bmjresp-2019-000484
M3 - Article
C2 - 32054641
SN - 2052-4439
VL - 7
JO - BMJ Open Respiratory Research
JF - BMJ Open Respiratory Research
IS - 1
M1 - e000484
ER -